Research programme: peptide-based therapeutics - Longevity Biotech

Drug Profile

Research programme: peptide-based therapeutics - Longevity Biotech

Alternative Names: LBT 3627; LBT-6030

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Longevity Biotech
  • Developer Longevity Biotech; University of Nebraska Medical Center
  • Class Neuroprotectants; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists; Vasoactive intestinal polypeptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease; Type 2 diabetes mellitus

Most Recent Events

  • 11 Oct 2017 Longevity Biotech in-licenses Hybridtide® platform technology from University of Wisconsin
  • 11 Oct 2017 Longevity Biotech has patent protection for Hybridtide® platform technology in USA
  • 11 Oct 2017 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top